Syndax Pharmaceuticals Inc. (SNDX) announced Wednesday morning that its ENCORE 601 study in patients with non-small cell lung cancer has met the pre-specified objective response threshold to advance into the second stage of the Phase 2 trial.
from RTT - Before the Bell http://ift.tt/2pZJr8l
via IFTTT
No comments:
Post a Comment